Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Age \>=20 and \<=75~2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, tubal cancer~3. Stage 3 or 4~4. WBC \>= 3500/mm3, ANC \>= 1500/mm3, platelet \>= 100000/mm3, hemoglobin \>= 10 g/dl~5. Serum creatinine \<= upper normal limit \* 1.25~6. Total bilirubin \<= 1.5mg/mm3, ALT/AST \<= upper normal limit \* 3, ALP \<= upper normal limit \* 3~7. Adequate compliance and geographical closeness which make adequate follow-up possible~8. GOG performance status 0-2~9. Anticipated survival \>= 3 months~10. Who agreed to participate in this study and signed on informed consent form~Exclusion criteria:~1. History of chemotherapy or radiotherapy on abdomen/pelvis area~2. Pleural/pericardial effusion, ascites causing respiratory difficulties \>= NCI-CTCAE grade 2~3. History of other cancers within 5 years~4. History of unapproved therapy within 30 days before enrollment~5. Other serious diseases which could threat the safety of participants or impair the ability of participants to complete the participation.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IP Chemotherapy (Type: EXPERIMENTAL): Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).